Ajooni Biotech (AJOONI)₹2.87−4.33%Animal Feed
In the Mar 2026 quarter (standalone), Ajooni Biotech reported sales of ₹60.76 Cr, up 107.2% from Mar 2025, and net profit of ₹0.94 Cr, down 39.4% year on year. For the year to Mar 2026, sales were ₹182 Cr and net profit ₹3.99 Cr.
Company filings, standalone accounts; latest reported quarter Mar 2026
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 21.07 | 19.55 | 20.11 | 19.63 | 25.73 | 25.78 | 34.12 | 29.33 | 31.34 | 31.83 | 58.87 | 60.76 |
| Expenses | 20.42 | 18.93 | 20.77 | 18.06 | 24.79 | 25.06 | 33.21 | 28.40 | 30.69 | 30.36 | 55.91 | 59.82 |
| Operating Profit | 0.67 | 0.64 | −0.66 | 1.60 | 0.97 | 0.78 | 0.94 | 1.02 | 0.72 | 1.51 | 3.04 | 1.02 |
| OPM % | 3.1% | 3.2% | −3.3% | 8.1% | 3.7% | 3.0% | 2.7% | 3.4% | 2.3% | 4.7% | 5.1% | 1.7% |
| Other Income | 0.08 | 0.30 | 1.58 | 0.27 | 0.05 | 0.32 | 0.40 | 1.35 | 0.66 | 0.16 | 0.33 | 1.31 |
| Interest | 0.14 | 0.20 | 0.13 | 0.12 | 0.16 | 0.07 | 0.08 | 0.07 | 0.09 | 0.18 | 0.19 | 0.30 |
| Depreciation | 0.20 | 0.22 | 0.20 | 0.23 | 0.21 | 0.22 | 0.23 | 0.37 | 0.24 | 0.26 | 0.80 | 0.91 |
| Profit before tax | 0.38 | 0.51 | 0.58 | 1.49 | 0.62 | 0.78 | 1.00 | 1.90 | 1.02 | 1.22 | 2.35 | 1.11 |
| Tax % | −2.6% | 23.0% | 23.7% | 38.6% | 25.3% | 22.7% | 27.7% | 19.3% | 24.2% | 24.3% | 30.0% | 15.1% |
| Net Profit | 0.39 | 0.39 | 0.45 | 0.92 | 0.48 | 0.61 | 0.74 | 1.55 | 0.77 | 0.92 | 1.66 | 0.94 |
| EPS (Rs) | 0.01 | 0.01 | 0.02 | 0.04 | 0.02 | 0.03 | 0.03 | 0.08 | 0.04 | 0.04 | 0.09 | 0.05 |
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 13.03 | 29.08 | 42.15 | 40.14 | 40.14 | 51.13 | 74.18 | 74.24 | 80.22 | 115 | 182 | 183 |
| Expenses | 13.06 | 28.10 | 41.19 | 39.15 | 39.16 | 49.16 | 71.27 | 72.32 | 78.29 | 112 | 177 | 177 |
| Operating Profit | 0.00 | 1.01 | 1.01 | 1.01 | 1.01 | 2.01 | 3.01 | 3.01 | 2.01 | 4.01 | 6.02 | 6.29 |
| OPM % | 1.7% | 2.4% | 2.2% | 1.7% | 3.1% | 3.2% | 4.2% | 3.7% | 2.8% | 3.2% | 3.4% | 3.4% |
| Other Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.01 | 2.01 | 2.01 | 2.46 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.01 | 1.01 | 0.00 | 1.01 | 0.00 | 1.01 | 0.76 |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.01 | 1.01 | 1.01 | 0.99 | 0.99 | 2.01 | 2.21 |
| Profit before tax | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.99 | 1.99 | 2.99 | 3.99 | 5.99 | 5.70 |
| Tax % | 28.9% | 28.0% | 19.9% | 15.0% | 29.0% | 26.0% | 27.9% | 27.9% | 27.9% | 22.0% | 25.0% | — |
| Exceptional items | 0.00 | 0.00 | 0.00 | 0.00 | −0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.99 | 1.01 | 2.01 | 3.01 | 3.99 | 4.29 |
| EPS (Rs) | 0.17 | 0.35 | 0.02 | 0.02 | 0.01 | 0.01 | 0.04 | 0.05 | 0.11 | 0.19 | 0.24 | 0.22 |
| Dividend payout % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0.23 | 0.23 | 0.32 | 5.98 | 5.98 | 7.97 | 9.97 | 9.96 | 17.94 | 17.94 | 33.87 | 33.87 |
| Reserves | 0.00 | 0.00 | 0.99 | 4.99 | 5.98 | 6.98 | 5.98 | 5.99 | 23.93 | 24.97 | 53.81 | 56.81 |
| Borrowings | 0.00 | 1.01 | 1.01 | 5.01 | 5.00 | 5.00 | 6.99 | 4.99 | 5.00 | 2.01 | 2.00 | 17.96 |
| Other Liabilities | 1.00 | 0.99 | 11.00 | 3.99 | 0.99 | 1.99 | 5.97 | 6.97 | 11.94 | 2.98 | 4.97 | 10.95 |
| Total Liabilities | 1.99 | 1.99 | 12.99 | 18.97 | 17.95 | 22.94 | 27.91 | 28.91 | 58.81 | 47.90 | 94.65 | 120 |
| Fixed Assets | 0.00 | 0.00 | 0.99 | 0.99 | 0.99 | 1.99 | 4.98 | 5.98 | 5.98 | 9.97 | 10.96 | 25.93 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.01 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 6.02 | 6.02 | 4.01 | 3.01 | 1.01 | 1.01 | 4.01 | 2.01 | 3.01 | 2.01 |
| Other Assets | 0.99 | 1.99 | 5.98 | 11.96 | 12.95 | 17.94 | 21.92 | 21.92 | 47.82 | 33.91 | 79.68 | 91.65 |
| Inventories | 0.35 | 0.40 | 4.20 | 1.99 | 5.05 | 3.28 | 5.36 | 5.86 | 6.96 | 15.31 | 23.88 | 39.28 |
| Trade receivables | 0.80 | 1.22 | 1.31 | 2.87 | 4.84 | 12.65 | 13.73 | 13.85 | 20.58 | 12.97 | 16.24 | 17.84 |
| Cash & equivalents | 0.12 | 0.06 | 0.09 | 5.28 | 0.72 | 0.11 | 0.23 | 0.05 | 0.30 | 0.42 | 6.81 | 0.41 |
| Total Assets | 1.99 | 1.99 | 12.99 | 18.97 | 17.95 | 22.94 | 27.91 | 28.91 | 58.81 | 47.90 | 94.65 | 120 |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operating activity | — | −0.99 | −2.99 | −2.99 | −4.98 | −3.98 | 0.99 | 3.99 | −5.98 | 22.90 | −17.94 | −5.97 |
| Cash from investing activity | — | 0.00 | −2.01 | 0.00 | 0.99 | 0.00 | −2.99 | −2.01 | −15.99 | 8.01 | −17.01 | −16.01 |
| Cash from financing activity | — | 0.99 | 4.99 | 7.98 | −0.99 | 2.99 | 1.99 | −1.99 | 21.96 | −3.99 | 24.92 | 14.96 |
| Net cash flow | — | 0.00 | 0.00 | 5.01 | −5.01 | −0.99 | 0.00 | 0.00 | 0.00 | 26.97 | −9.99 | −5.99 |
| Capex | 0.24 | 0.18 | 0.00 | 0.00 | 0.29 | 1.41 | 3.54 | 2.13 | 2.87 | 5.62 | 2.04 | 18.07 |
| Free cash flow | — | −0.99 | −2.99 | −2.99 | −4.98 | −5.98 | −1.99 | 1.99 | −7.97 | 16.93 | −18.94 | −22.90 |
| CFO / OP % | — | −257.1% | −427.1% | −284.1% | −706.1% | −353.1% | 70.9% | 124.9% | −185.0% | 1,047.0% | −458.0% | −92.0% |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor days | 40 | 33 | 17 | 25 | 44 | 115 | 98 | 68 | 101 | 59 | 52 | 36 |
| Inventory days | 21 | 13 | 62 | 18 | 50 | 33 | 45 | 33 | 38 | 79 | 89 | 96 |
| Days payable | 65 | 26 | 78 | 8 | 11 | 19 | 45 | 38 | 55 | 7 | 12 | 21 |
| Cash conversion cycle | −5 | 19 | 0 | 34 | 83 | 128 | 97 | 62 | 82 | 130 | 128 | 110 |
| Working capital days | 6 | 10 | −28 | 0 | 85 | 106 | 78 | 59 | 95 | 133 | 161 | 94 |
| ROCE % | 28.0% | 18.0% | 37.0% | 10.0% | 4.0% | 4.0% | 5.0% | 9.0% | 6.0% | 8.0% | 7.0% | 6.0% |
For the Mar 2026 quarter, Ajooni Biotech reported sales of ₹60.76 Cr, up 107.2% year on year and net profit of ₹0.94 Cr, down 39.4% year on year. The operating margin was 1.7%.
Ajooni Biotech's sales for the year to Mar 2026 were ₹182 Cr; over the last twelve months they were ₹183 Cr.
Net profit for the year to Mar 2026 was ₹3.99 Cr, and ₹4.29 Cr over the last twelve months. Earnings per share over the same trailing period were ₹0.22.
Ajooni Biotech reported borrowings of ₹17.96 Cr at Mar 2026, against cash and equivalents of ₹0.41 Cr.
Cash from operations was −₹5.97 Cr in the year to Mar 2026; after capital spending, free cash flow was −₹22.90 Cr.